Voractiv: quadruple TB combination tablet

Voractiv (rifampicin/isoniazid/pyrazinamide/ethambutol) is a fixed-dose combination tablet containing four antibacterial agents that have antimicrobial activity against Mycobacterium tuberculosis.

Voractiv contains rifampicin 150mg, isoniazid 75mg, pyrazinamide 400mg and ethambutol 275mg
Voractiv contains rifampicin 150mg, isoniazid 75mg, pyrazinamide 400mg and ethambutol 275mg

Voractiv is licensed for the treatment of TB during the initial intensive phase, in accordance with WHO guidelines.

Rifampicin is a rifamycin antibiotic. Isoniazid, pyrazinamide and ethambutol are bactericidal antituberculous agents.

Voractiv is given once daily for 2 months, with or without concomitant streptomycin. Treatment is then continued with rifampicin/isoniazid, isoniazid/ethambutol or rifampicin/isoniazid/ethambutol.

View Voractiv drug record

Further information: Genus Pharmaceuticals

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more